Can MEI Pharma Rise Nearly 300%?
MEI Pharma, Inc. (NASDAQ: MEIP) saw its shares make a solid gain on Thursday after the company received a crucial upgrade from Oppenheimer. Most analysts only issue price targets that are within anywhere from…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 168
Big Pharma Has Big Catalysts Coming for the Rest of 2017
A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow they have for the rest of 2017.
Short Sellers Raise the Stakes in Major Biotechs
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Major Pharma Short Interest Surges
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly upward.
What to Expect From Eli Lilly at ASCO
24/7 Wall St. takes a look at Eli Lilly, and what Credit Suisse sees happening for this pharma giant at ASCO.
Why Inovio Pharmaceuticals May Be the Next Big Thing
Shares of Inovio Pharmaceuticals saw a massive gain early on Wednesday after the company announced a critical update from its HIV vaccine.
What Analysts Have to Say About Agilent Technologies After Earnings
After Agilent Technologies reported its quarterly financial results late on Monday, investors were very happy with the beats on both the top and bottom lines. Analysts also took this opportunity to lift their price…
An STD Test People Can Do at Home
Testing for sexually transmitted diseases has become easier and more discrete as a new company has launched a home test kit.
JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
Why Endologix Shares Are Hitting a Multiyear Low
Endologix saw its shares hit a multiyear low following a meeting with the FDA concerning its Nellix Endovascular Aneurysm Sealing System.
How ASCO Could Make or Break These 5 Cancer Drug Trials
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) has the potential to make or break companies, with winners walking away from this event with a nice gain and losers trying…
Why This Humira Patent Loss Might Not Be What You Think
AbbVie watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office's Trial and Appeals Board that found in favor of Coherus Biosciences.
Why Syndax Shares Are Rallying
Syndax Pharmaceuticals has announced that Encore 601 has met the prespecified objective response threshold to advance into the second stage of the Phase 2 trial and will reopen enrollment immediately.
Is Editas Facing a New Reality in CRISPR Land?
Big opportunities in emerging health care companies often come with very bumpy rides. There is also the risk, of course, that there are no assurances that the potential promise and upside will come true…
Why Akebia Shares Are Hitting New Highs
Akebia Therapeutics saw its shares hit a new 52-week high in Tuesday’s session following a key licensing agreement with Vifor Pharma.